Last reviewed · How we verify
Vytorin
At a glance
| Generic name | Vytorin |
|---|---|
| Also known as | Ezetimibi/Simvastatin 10/40, Ezetimibe/Simvastatin, Vytorin 10/40, SCH 465981, ezetimibe |
| Sponsor | University at Buffalo |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer (PHASE2)
- Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis (PHASE2)
- A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)
- A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038) (PHASE3)
- Eze/Simva Switch Study in Diabetics (0653A-807) (PHASE3)
- Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED) (PHASE3)
- Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148) (PHASE3)
- A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vytorin CI brief — competitive landscape report
- Vytorin updates RSS · CI watch RSS
- University at Buffalo portfolio CI